{"id":164138,"date":"2026-01-20T06:00:58","date_gmt":"2026-01-20T05:00:58","guid":{"rendered":"https:\/\/semmelweis.hu\/hirek\/?p=164138"},"modified":"2026-01-22T07:59:37","modified_gmt":"2026-01-22T06:59:37","slug":"tudomanyos-hirado-29","status":"publish","type":"post","link":"https:\/\/semmelweis.hu\/hirek\/2026\/01\/20\/tudomanyos-hirado-29\/","title":{"rendered":"Tudom\u00e1nyos h\u00edrad\u00f3 29."},"content":{"rendered":"<div class=\"lead\"><strong>Tudom\u00e1nyos h\u00edrad\u00f3 c\u00edm\u0171 cikksorozatunkban az egyetemhez k\u00f6thet\u0151 D1 min\u0151s\u00edt\u00e9s\u0171 tudom\u00e1nyos k\u00f6zlem\u00e9nyekr\u0151l olvashat\u00f3 r\u00f6vid \u00f6sszefoglal\u00f3. A cikkeket az elm\u00falt id\u0151szak megjelen\u00e9sei alapj\u00e1n a K\u00f6zponti K\u00f6nyvt\u00e1r, illetve a tudom\u00e1nyos \u00e9s innov\u00e1ci\u00f3s rektorhelyettes\u00a0v\u00e1logatta.<\/strong><\/div>\n<div class=\"keretes w-100\">\n<h3>Tartalomjegyz\u00e9k<\/h3>\n<ul>\n<li><a href=\"#betegek\">A betegek, gondoz\u00f3k \u00e9s a nyilv\u00e1noss\u00e1g bevon\u00e1s\u00e1nak hat\u00e1sa a randomiz\u00e1lt klinikai vizsg\u00e1latok integrit\u00e1s\u00e1ra \u2013 eserny\u0151tanulm\u00e1ny<\/a><\/li>\n<li><a href=\"#stressz\">A k\u00f6rnyezeti stressz hi\u00e1ny\u00e1ban kialakul\u00f3 depresszi\u00f3s t\u00fcnetek genetikai vizsg\u00e1lata<\/a><\/li>\n<li><a href=\"#szivtapasz\">Olvad\u00e9k-elektro\u00edr\u00e1ssal (melt electrowriting) k\u00e9sz\u00fclt, k\u00f6zepes l\u00e1nchossz\u00fas\u00e1g\u00fa polihidroxi-alkano\u00e1tb\u00f3l (MCL-PHA) \u00e1ll\u00f3 sz\u00edvregener\u00e1l\u00f3 foltok sz\u00edvinfarktus (MI) ut\u00e1ni alkalmaz\u00e1sra<\/a><\/li>\n<li><a href=\"#verkep\">V\u00e9rk\u00e9p alap\u00fa immun-markerek id\u0151beli v\u00e1ltoz\u00e1sainak elemz\u00e9se vastag- \u00e9s v\u00e9gb\u00e9l tumorokban<\/a><\/li>\n<li><a href=\"#dohanyzas\">A doh\u00e1nyz\u00e1ssal \u00f6sszef\u00fcgg\u0151 genetikai vari\u00e1nsok hat\u00e1sa a fizikai terhel\u00e9st k\u00f6vet\u0151 sz\u00edvfrekvencia v\u00e1ltoz\u00e1sra<\/a><\/li>\n<li><a href=\"#intraoralis\">Az intraor\u00e1lis szkennel\u00e9s, a sz\u00e1m\u00edt\u00f3g\u00e9p vez\u00e9relt gy\u00e1rt\u00e1s \u00e9s a teljes munkafolyamat pontoss\u00e1g m\u00e9r\u00e9s\u00e9nek egys\u00e9ges\u00edt\u00e9se virtu\u00e1lis illeszt\u00e9s m\u00f3dszer\u00e9vel sz\u00f3l\u00f3 korona eset\u00e9n<\/a><\/li>\n<li><a href=\"#prope\">A proPE rendszerrel m\u00e9g pontosabb\u00e1 \u00e9s biztons\u00e1gosabb\u00e1 v\u00e1lhat a g\u00e9nszerkeszt\u00e9s<\/a><\/li>\n<li><a href=\"#hasnyalmirigy\">A cholecystectomia \u00e9s az endoszk\u00f3pos retrogr\u00e1d cholangiopancreatographia (ERCP) biztons\u00e1g\u00e1nak \u00e9s hat\u00e9konys\u00e1g\u00e1nak vizsg\u00e1lata epek\u00f6vess\u00e9g okozta hasny\u00e1lmirigy-gyullad\u00e1sban a terhess\u00e9g sor\u00e1n: BORN vizsg\u00e1lat<\/a><\/li>\n<li><a href=\"#markerpredict\">\u00daj megk\u00f6zel\u00edt\u00e9s daganatter\u00e1pi\u00e1k hat\u00e9konys\u00e1g\u00e1nak el\u0151rejelz\u00e9s\u00e9re biomarkerek rendszerszint\u0171 azonos\u00edt\u00e1s\u00e1val<\/a><\/li>\n<li><a href=\"#toll\">A Toll-like receptorok, antimikrobi\u00e1lis feh\u00e9rj\u00e9k \u00e9s b\u00e9lny\u00e1lkah\u00e1rty\u00e1t bor\u00edt\u00f3 bakteri\u00e1lis biofilm v\u00e1ltoz\u00e1sainak vizsg\u00e1lata a nem-szteroid gyullad\u00e1scs\u00f6kkent\u0151k \u00e1ltal okozott b\u00e9lk\u00e1rosod\u00e1s \u00e1llatk\u00eds\u00e9rletes modellj\u00e9ben<\/a><\/li>\n<li><a href=\"#pitvari\">Az atorvasztatin hat\u00e1sa a bal pitvari funkci\u00f3ra antraciklin alap\u00fa kemoter\u00e1pi\u00e1ban<\/a><\/li>\n<\/ul>\n<\/div>\n<h3><a id=\"betegek\"><\/a>A betegek, gondoz\u00f3k \u00e9s a nyilv\u00e1noss\u00e1g bevon\u00e1s\u00e1nak hat\u00e1sa a randomiz\u00e1lt klinikai vizsg\u00e1latok integrit\u00e1s\u00e1ra \u2013 eserny\u0151tanulm\u00e1ny<\/h3>\n<p><a href=\"https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/Figure-2.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft size-medium wp-image-164140\" src=\"https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/Figure-2-379x400.jpg\" alt=\"\" width=\"379\" height=\"400\" srcset=\"https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/Figure-2-379x400.jpg 379w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/Figure-2.jpg 624w\" sizes=\"auto, (max-width: 379px) 100vw, 379px\" \/><\/a>A bizony\u00edt\u00e9kon alap\u00fa orvosl\u00e1s legfontosabb tudom\u00e1nyos alappill\u00e9rei a randomiz\u00e1lt klinikai vizsg\u00e1latok (angolul: randomised clinical trial, RCT). A kutat\u00e1si integrit\u00e1s az etikai \u00e9s szakmai norm\u00e1k betart\u00e1s\u00e1t, a felel\u0151ss\u00e9gteljes kutat\u00f3munk\u00e1t jelenti. A k\u00fcl\u00f6nb\u00f6z\u0151 nemzeti- \u00e9s nemzetk\u00f6zi ir\u00e1nyelvek, k\u00f6zt\u00fck a Helsinki Nyilatkozat 2024-ben elfogadott verzi\u00f3ja is elengedhetetlennek tartja a betegek, a gondoz\u00f3k \u00e9s a nyilv\u00e1noss\u00e1g bevon\u00e1s\u00e1t az RCT-k tervez\u00e9s\u00e9be (angolul: patient, carer and public involvement, PCPI). Hogy meg\u00e9rts\u00fck mik az \u00f6sszef\u00fcgg\u00e9sek a PCPI \u00e9s az RCT-k integrit\u00e1sa k\u00f6z\u00f6tt, egy eserny\u0151\u00e1ttekint\u00e9st v\u00e9gezt\u00fcnk. Kutat\u00e1saink sor\u00e1n 27 szisztematikus \u00e1ttekint\u00e9st, \u00edgy k\u00f6zvetve t\u00f6bb, mint 958 tanulm\u00e1nyt elemezt\u00fcnk ki. A betegek bevon\u00e1s\u00e1nak 33 el\u0151ny\u00f6s, \u00e9s 14 h\u00e1tr\u00e1nyos hat\u00e1s\u00e1t azonos\u00edtottuk az RCT-k integrit\u00e1s\u00e1ra n\u00e9zve.<\/p>\n<p>A jelenleg rendelkez\u00e9sre \u00e1ll\u00f3 bizony\u00edt\u00e9kok alapj\u00e1n a PCPI legismertebb el\u0151nye, hogy n\u00f6veli az RCT-k t\u00e1rsadalmi elfogadhat\u00f3s\u00e1g\u00e1t (pl. kultur\u00e1lisan \u00e9rz\u00e9keny tervez\u00e9s, \u00f6sszhang a k\u00f6z\u00f6ss\u00e9gi elv\u00e1r\u00e1sok \u00e9s kutat\u00e1sok k\u00f6z\u00f6tt). Ezen t\u00fal seg\u00edts\u00e9get ny\u00fajthat a kutat\u00e1si priorit\u00e1sok fel\u00e1ll\u00edt\u00e1s\u00e1ban, az er\u0151forr\u00e1sok megfelel\u0151 eloszt\u00e1s\u00e1ban, n\u00f6veli az elsz\u00e1moltathat\u00f3s\u00e1got a finansz\u00edroz\u00f3k \u00e9s a ny\u00edlv\u00e1noss\u00e1g fel\u00e9, valamint jav\u00edt az eredm\u00e9nyek helyt\u00e1ll\u00f3s\u00e1g\u00e1n. A legfontosabb h\u00e1tr\u00e1nyok t\u00f6bbnyire megel\u0151zhet\u0151ek, \u00e9s a PCPI nem megfelel\u0151 megval\u00f3s\u00edt\u00e1s\u00e1val \u00e1llnak \u00f6sszef\u00fcgg\u00e9sben, mint p\u00e9ld\u00e1ul a bevont betegcsoport nem reprezentat\u00edv \u00f6sszet\u00e9tele, a felsz\u00ednes bevon\u00e1s puszt\u00e1n a p\u00e1ly\u00e1zati sikerek kedv\u00e9\u00e9rt, vagy a nem egy\u00e9rtelm\u0171 szerepekb\u0151l ad\u00f3d\u00f3 fesz\u00fclts\u00e9gek. Egyel\u0151re m\u00e9g kev\u00e9s ismeret \u00e1ll rendelkez\u00e9sre arr\u00f3l, hogy mi a PCPI szerepe az RCT-k nyomon k\u00f6vet\u00e9s\u00e9ben, szab\u00e1lyoz\u00e1s\u00e1ban, valamint a kutat\u00e1si vissza\u00e9l\u00e9sekkel kapcsolatos probl\u00e9m\u00e1k kezel\u00e9s\u00e9ben. Tanulm\u00e1nyaink eredm\u00e9nyei alapj\u00e1ul szolg\u00e1lhatnak egy nemzetk\u00f6zi ir\u00e1nyelv kidolgoz\u00e1s\u00e1nak a kutat\u00e1si integrit\u00e1s jav\u00edt\u00e1s\u00e1nak \u00e9rdek\u00e9ben &#8211; \u00edrta \u00f6sszefoglal\u00f3j\u00e1ban dr. Juh\u00e1sz Bal\u00e1zs.<\/p>\n<div class=\"keretes w-100\">\n<p>Randomised clinical trials integrity and patient, carer and public involvement: A scoping umbrella review<br \/>\nBal\u00e1zs Juh\u00e1sz (a Department of Preventive Medicine and Public Health, University of Granada; Department of Family Medicine, Semmelweis University), Klejda Harasanic (Department of Pharmacy, University of Medicine), Sandra Mart\u00edn-Pel\u00e1eza (Department of Preventive Medicine and Public Health, University of Granada; CIBER Epidemiolog\u00eda y Salud P\u00fablica &lt;CIBERESP&gt;;, Instituto de Salud Carlos III &lt;ISCIII&gt;; Instituto de Investigaci\u00f3n Biosanitaria de Granada &lt;ibs.GRANADA&gt;), Naomi Cano-Ib\u00e1\u00f1eza (Department of Preventive Medicine and Public Health, University of Granada; CIBER Epidemiolog\u00eda y Salud P\u00fablica &lt;CIBERESP&gt;; Instituto de Salud Carlos III &lt;ISCIII&gt;; Instituto de Investigaci\u00f3n Biosanitaria de Granada &lt;ibs.GRANADA&gt;), Patrick Chien (Department of Obstetrics and Gynecology, RCSI and UCD Malaysia Campus), Mohamed Fawzy (IbnSina &lt;Sohag&gt;; Banon &lt;Assiut&gt;; Qena &lt;Qena&gt;; Amshag &lt;Sohag&gt; IVF Facilities), Khalid Saeed Khan (Department of Preventive Medicine and Public Health, University of Granada; CIBER Epidemiolog\u00eda y Salud P\u00fablica &lt;CIBERESP&gt;; Instituto de Salud Carlos III &lt;ISCIII&gt;), Aurora Bueno-Cavanillas (Department of Preventive Medicine and Public Health, University of Granada; CIBER Epidemiolog\u00eda y Salud P\u00fablica &lt;CIBERESP&gt;; Instituto de Salud Carlos III &lt;ISCIII&gt;; Instituto de Investigaci\u00f3n Biosanitaria de Granada &lt;ibs.GRANADA&gt;)<br \/>\nAccountability in Research, 1\u201322.<br \/>\n<a href=\"https:\/\/doi.org\/10.1080\/08989621.2025.2544338\" target=\"_blank\" rel=\"noopener\">https:\/\/doi.org\/10.1080\/08989621.2025.2544338<\/a><\/p>\n<\/div>\n<h3><a id=\"stressz\"><\/a>A k\u00f6rnyezeti stressz hi\u00e1ny\u00e1ban kialakul\u00f3 depresszi\u00f3s t\u00fcnetek genetikai vizsg\u00e1lata<\/h3>\n<p><a href=\"https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/NoStress.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft size-medium wp-image-164141\" src=\"https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/NoStress-400x213.jpg\" alt=\"\" width=\"400\" height=\"213\" srcset=\"https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/NoStress-400x213.jpg 400w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/NoStress-900x479.jpg 900w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/NoStress-768x409.jpg 768w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/NoStress-1536x818.jpg 1536w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/NoStress-2048x1091.jpg 2048w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/NoStress-753x401.jpg 753w\" sizes=\"auto, (max-width: 400px) 100vw, 400px\" \/><\/a>A depresszi\u00f3 sokarc\u00fa betegs\u00e9g: egyes esetekben stressz v\u00e1ltja ki, m\u00e1skor l\u00e1tsz\u00f3lag ok n\u00e9lk\u00fcl jelentkezik. E heterogenit\u00e1s miatt neh\u00e9z a depresszi\u00f3 kezel\u00e9se, a h\u00e1tt\u00e9rben szerepet j\u00e1tsz\u00f3 okok alapj\u00e1n t\u00f6rt\u00e9n\u0151 alt\u00edpusok defini\u00e1l\u00e1sa alapj\u00e1n viszont k\u00f6nnyebben meg\u00e9rthetj\u00fck ezek neurobiol\u00f3giai-genetikai alapjait. Jelen kutat\u00e1sunkban a stresszt\u0151l f\u00fcggetlen\u00fcl kialakul\u00f3 depresszi\u00f3s t\u00fcnetek genetikai h\u00e1tter\u00e9t vizsg\u00e1ltuk a UK Biobank t\u00f6bb mint 200 ezer r\u00e9sztvev\u0151j\u00e9n, akik az elm\u00falt k\u00e9t \u00e9vben nem \u00e9ltek \u00e1t stresszt.<\/p>\n<p>Teljes genomot \u00e1tfog\u00f3 elemz\u00e9s (GWAS) sor\u00e1n t\u00f6bb mint 6,076,829 vari\u00e1nst elemezt\u00fcnk. A leger\u0151sebb \u00f6sszef\u00fcgg\u00e9st a DCC g\u00e9n egyik vari\u00e1nsa eset\u00e9ben azonos\u00edtottuk, de m\u00e1s g\u00e9nekben is tal\u00e1ltunk teljes genom szinten szignifik\u00e1ns vari\u00e1nsokat. A stressz n\u00e9lk\u00fcl megjelen\u0151 depresszi\u00f3s t\u00fcnetekkel \u00f6sszef\u00fcgg\u0151 g\u00e9nek szingifik\u00e1ns upregul\u00e1ci\u00f3t mutatnak sz\u00e1mos, depresszi\u00f3 szempontj\u00e1b\u00f3l fontos agyter\u00fcleten, a front\u00e1lis \u00e9s anterior cingul\u00e1ris kortexben. Az eredm\u00e9nyek szerint a stresszt\u0151l f\u00fcggetlen\u00fcl megjelen\u0151 depresszi\u00f3 molekul\u00e1ris \u00f6r\u00f6kletess\u00e9ge 7.3%. A kutat\u00e1s seg\u00edt elk\u00fcl\u00f6n\u00edteni a depresszi\u00f3 alt\u00edpusait, ami k\u00f6zelebb visz a szem\u00e9lyre szabott diagn\u00f3zishoz \u00e9s kezel\u00e9shez. A tanulm\u00e1ny hangs\u00falyozza: a genetika \u00e9s k\u00f6rnyezet sz\u00e9tv\u00e1laszt\u00e1sa cs\u00f6kkenti a &#8222;zajt&#8221; a kutat\u00e1sokban, jobb ter\u00e1pi\u00e1kat \u00edg\u00e9rve &#8211; fogalmazott dr. Gonda X\u00e9nia.<\/p>\n<div class=\"keretes w-100\">\n<p>Disentangling nature and nurture: Exploring the genetic background of depressive symptoms in the absence of recent stress exposure using a GWAS approach<br \/>\nBerta Erdelyi-Hamza (Semmelweis University Doctoral School, Mental Health Sciences Division), Dora Torok (Semmelweis University Doctoral School, Pharmaceutical Sciences and Health Technologies Division; Department of Pharmacodynamics, Faculty\u00a0 eis University; NAP3.0-SE Neuropsychopharmacology Research Group, Hungarian Brain Research Program, Semmelweis University), Sandor Krause (Semmelweis University Doctoral School, Mental Health Sciences Division; Department of Pharmacodynamics, Faculty of Pharmaceutical Sciences, Semmelweis University; Center of Pharmacology and Drug Research &amp; Development, Semmelweis University), Nora Eszlari (Department of Pharmacodynamics, Faculty of Pharmaceutical Sciences, Semmelweis University; Center of Pharmacology and Drug Research &amp; Development, Semmelweis University; NAP3.0-SE Neuropsychopharmacology Research Group, Hungarian Brain Research Program, Semmelweis University), Gyorgy Bagdy (Department of Pharmacodynamics, Faculty of Pharmaceutical Sciences, Semmelweis University; Center of Pharmacology and Drug Research &amp; Development, Semmelweis University; NAP3.0-SE Neuropsychopharmacology Research Group, Hungarian Brain Research Program, Semmelweis University), Gabriella Juhasz (Department of Pharmacodynamics, Faculty of Pharmaceutical Sciences, Semmelweis University; Center of Pharmacology and Drug Research &amp; Development, Semmelweis University; NAP3.0-SE Neuropsychopharmacology Research Group, Hungarian Brain Research Program, Semmelweis University), Xenia Gonda (Department of Pharmacodynamics, Faculty of Pharmaceutical Sciences, Semmelweis University; Center of Pharmacology and Drug Research &amp; Development, Semmelweis University; NAP3.0-SE Neuropsychopharmacology Research Group, Hungarian Brain Research Program, Semmelweis University; Department of Psychiatry and Psychotherapy, Semmelweis University; Department of Clinical Psychology, Semmelweis University)<br \/>\nJournal of Affective Disorders, Volume 388, 1 November 2025, 119731<br \/>\n<a href=\"https:\/\/doi.org\/10.1016\/j.jad.2025.119731\" target=\"_blank\" rel=\"noopener\">https:\/\/doi.org\/10.1016\/j.jad.2025.119731<\/a><\/p>\n<\/div>\n<h3><a id=\"szivtapasz\"><\/a>Olvad\u00e9k-elektro\u00edr\u00e1ssal (melt electrowriting) k\u00e9sz\u00fclt, k\u00f6zepes l\u00e1nchossz\u00fas\u00e1g\u00fa polihidroxi-alkano\u00e1tb\u00f3l (MCL-PHA) \u00e1ll\u00f3 sz\u00edvregener\u00e1l\u00f3 foltok sz\u00edvinfarktus (MI) ut\u00e1ni alkalmaz\u00e1sra<\/h3>\n<p><a href=\"https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/szivtapasz.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft size-medium wp-image-164148\" src=\"https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/szivtapasz-400x400.jpg\" alt=\"\" width=\"400\" height=\"400\" srcset=\"https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/szivtapasz-400x400.jpg 400w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/szivtapasz-800x800.jpg 800w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/szivtapasz-200x200.jpg 200w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/szivtapasz-768x768.jpg 768w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/szivtapasz-753x753.jpg 753w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/szivtapasz.jpg 853w\" sizes=\"auto, (max-width: 400px) 100vw, 400px\" \/><\/a>A k\u00e1rosodott sz\u00edv regener\u00e1ci\u00f3j\u00e1nak egyik m\u00f3dja lehet az, hogy megfelel\u0151 sejtt\u00edpusokat term\u00e9szetes vagy szintetikus, biokompatibilis anyagokkal kombin\u00e1lva stimul\u00e1lhatjuk a sejtek funkcion\u00e1lis \u00e9s struktur\u00e1lis \u00e9r\u00e9s\u00e9t, \u00e9s \u00edgy a sz\u00f6vetek regener\u00e1ci\u00f3j\u00e1t. Nyolc eur\u00f3pai egyetem egy\u00fcttm\u0171k\u00f6d\u00e9s\u00e9ben k\u00e9sz\u00fclt tanulm\u00e1nyban hum\u00e1n pluripotens \u0151ssejtekb\u0151l sz\u00e1rmaz\u00f3 sz\u00edvizomsejteket \u00e9s mikrovaszkul\u00e1ris endothelsejteket hoztunk l\u00e9tre, majd azokat egy polihidroxi-alk\u00e1n-alap\u00fa polimer m\u00e1trixra \u00fcltetve egy h\u00e1romdimenzi\u00f3s \u201esz\u00edvtapaszt\u201d fejlesztett\u00fcnk ki, \u00e9s \u00e9rt\u00e9kelt\u00fck annak a sz\u00edvregener\u00e1ci\u00f3t el\u0151seg\u00edt\u0151 potenci\u00e1lj\u00e1t egy in vivo eg\u00e9r sz\u00edvel\u00e9gtelens\u00e9g modellben.<\/p>\n<p>Az epikardi\u00e1lisan be\u00fcltetett endothelsejteket tartalmaz\u00f3 tapaszok j\u00f3l toler\u00e1lhat\u00f3ak voltak \u00e9s seg\u00edts\u00e9g\u00fckkel siker\u00fclt megind\u00edtani az infarktus r\u00e9szleges vaszkul\u00e1ris regener\u00e1ci\u00f3j\u00e1t, ahogy ezt a hegben megjelen\u0151 kis kapill\u00e1risok jelezt\u00e9k. A sz\u00edv infarktust k\u00f6vet\u0151 sz\u00edvel\u00e9gtelens\u00e9g el\u0151rehalad\u00e1s\u00e1t azonban ezen els\u0151 k\u00eds\u00e9rletekben ez a tapasz nem akad\u00e1lyozta meg &#8211; \u00edrta \u00f6sszefoglal\u00f3j\u00e1ban dr. F\u00f6ldes G\u00e1bor.<\/p>\n<div class=\"keretes w-100\">\n<p>Melt electrowritten medium chain length polyhydroxyalkanoate cardiac patches for Post-MI cardiac regeneration<br \/>\nQasim A. Majid (National Heart and Lung Institute, Faculty of Medicine, Imperial College London; Drug Research Programme, Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki), Pragati Pandey (National Heart and Lung Institute, Faculty of Medicine, Imperial College London), Mohamed Bellahcene (National Heart and Lung Institute, Faculty of Medicine, Imperial College London), Christopher L. Grigsby (Department of Medical Biochemistry and Biophysics, Karolinska Institute; School of Pharmacy, Queens University Belfast), Molly M. Stevens (Department of Medical Biochemistry and Biophysics, Karolinska Institute; Department of Materials, Department of Bioengineering and Institute of Biomedical Engineering, Imperial College London), Virpi Talman (National Heart and Lung Institute, Faculty of Medicine, Imperial College London; Drug Research Programme, Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki; Research Centre for Integrative Physiology &amp; Pharmacology, Institute of Biomedicine, University of Turku), Daniel J. Stuckey (Centre for Advanced Biomedical Imaging, Division of Medicine, University College London), G\u00e1bor F\u00f6ldes (National Heart and Lung Institute, Faculty of Medicine, Imperial College London; Heart and Vascular Center, Semmelweis University)<br \/>\nMaterials Today Bio, Volume 34, October 2025, 102256<br \/>\n<a href=\"https:\/\/doi.org\/10.1016\/j.mtbio.2025.102256\" target=\"_blank\" rel=\"noopener\">https:\/\/doi.org\/10.1016\/j.mtbio.2025.102256<\/a><\/p>\n<\/div>\n<h3><a id=\"verkep\"><\/a>V\u00e9rk\u00e9p alap\u00fa immun-markerek id\u0151beli v\u00e1ltoz\u00e1sainak elemz\u00e9se vastag- \u00e9s v\u00e9gb\u00e9l tumorokban<\/h3>\n<p><a href=\"https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/Herold_et_al_-_CRC_MedSci_-_Tud_Hirado.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft size-medium wp-image-164314\" src=\"https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/Herold_et_al_-_CRC_MedSci_-_Tud_Hirado-400x392.png\" alt=\"\" width=\"400\" height=\"392\" srcset=\"https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/Herold_et_al_-_CRC_MedSci_-_Tud_Hirado-400x392.png 400w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/Herold_et_al_-_CRC_MedSci_-_Tud_Hirado-815x800.png 815w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/Herold_et_al_-_CRC_MedSci_-_Tud_Hirado-768x753.png 768w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/Herold_et_al_-_CRC_MedSci_-_Tud_Hirado-1536x1507.png 1536w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/Herold_et_al_-_CRC_MedSci_-_Tud_Hirado-2048x2009.png 2048w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/Herold_et_al_-_CRC_MedSci_-_Tud_Hirado-753x739.png 753w\" sizes=\"auto, (max-width: 400px) 100vw, 400px\" \/><\/a>Annak ellen\u00e9re, hogy a vastag- \u00e9s v\u00e9gb\u00e9lr\u00e1k (CRC) vil\u00e1gszerte a harmadik leggyakoribb daganatt\u00edpus, olyan biomarkert, mellyel a betegs\u00e9g k\u00f6nnyen felismerhet\u0151 \u00e9s\/vagy annak lefoly\u00e1sa egyszer\u0171en \u00e9s olcs\u00f3n k\u00f6vethet\u0151, m\u00e1ig sem siker\u00fclt meghat\u00e1rozni. Az elm\u00falt \u00e9vtizedekben sz\u00e1mos kutat\u00e1s felvetette, hogy e c\u00e9lra \u00e9rdemes olyan biomarkereket vizsg\u00e1lni, melyek a rutin onkol\u00f3gi\u00e1ban is haszn\u00e1latos laborparam\u00e9tereken alapulnak. Ilyen biomarkerek a jelen kutat\u00e1sban is vizsg\u00e1lt p\u00e1n-immun gyullad\u00e1sos \u00e9rt\u00e9k (PIV), a sziszt\u00e9m\u00e1s immun-gyullad\u00e1s index (SII) \u00e9s a prognosztikus t\u00e1pl\u00e1lkoz\u00e1si index (PNI) is. Mindh\u00e1rom biomarker sz\u00e1m\u00edt\u00e1s\u00e1hoz a teljes v\u00e9rk\u00e9pben tal\u00e1lhat\u00f3 param\u00e9tereket, illetve a PNI eset\u00e9ben m\u00e9g a sz\u00e9rum albumin szinteket haszn\u00e1lt\u00e1k fel. Mindegyikre igaz, hogy v\u00e1ltoz\u00e1suk a tumoros megbeteged\u00e9s progresszi\u00f3j\u00e1t jelzi.<\/p>\n<p>Vizsg\u00e1latunkban els\u0151k\u00e9nt \u00edrtuk le, hogy e h\u00e1rom biomarker mik\u00e9nt v\u00e1ltozik a betegs\u00e9g lefoly\u00e1sa sor\u00e1n. E c\u00e9lb\u00f3l 835 CRC beteg, t\u00f6bb mint 4000 laborat\u00f3riumi adatait dolgoztuk fel. A megfigyelt v\u00e1ltoz\u00e1sok alapj\u00e1n olyan tendenci\u00e1t igazoltunk, melyek el\u0151seg\u00edtik a betegs\u00e9g progresszi\u00f3j\u00e1nak korai felismer\u00e9s\u00e9t, t\u00e1mogatva a klinikust a daganatellenes kezel\u00e9s optimaliz\u00e1l\u00e1s\u00e1ra hozott d\u00f6nt\u00e9seiben &#8211; \u00edrta \u00f6sszefoglal\u00f3j\u00e1ban dr. Herold Zolt\u00e1n.<\/p>\n<div class=\"keretes w-100\">\n<p>Are Calculated Immune Markers with or Without Comorbidities Good Predictors of Colorectal Cancer Survival? The Results of a Longitudinal Study<br \/>\nZoltan Herold (Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University), Magdolna Herold (Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University), Gyongyver Szentmartoni (Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University), Reka Szalasy (Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University), Julia Lohinszky (Department of Internal Medicine and Hematology, Semmelweis University), Aniko Somogyi (Department of Internal Medicine and Hematology, Semmelweis University), Attila Marcell Szasz (Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University; Department of Medical Oncology, Semmelweis University; National Institute of Oncology), Magdolna Dank (Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University; Department of Medical Oncology, Semmelweis University; National Institute of Oncology)<br \/>\nMed. Sci. 2025, 13(3), 108; <br \/>\n<a href=\"https:\/\/doi.org\/10.3390\/medsci13030108\" target=\"_blank\" rel=\"noopener\">https:\/\/doi.org\/10.3390\/medsci13030108<\/a><\/p>\n<\/div>\n<h3><a id=\"dohanyzas\"><\/a>A doh\u00e1nyz\u00e1ssal \u00f6sszef\u00fcgg\u0151 genetikai vari\u00e1nsok hat\u00e1sa a fizikai terhel\u00e9st k\u00f6vet\u0151 sz\u00edvfrekvencia v\u00e1ltoz\u00e1sra<\/h3>\n<p><a href=\"https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/RS39152_smoking-1026559_1920_scl.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft size-medium wp-image-164153\" src=\"https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/RS39152_smoking-1026559_1920_scl-400x267.jpg\" alt=\"\" width=\"400\" height=\"267\" srcset=\"https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/RS39152_smoking-1026559_1920_scl-400x267.jpg 400w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/RS39152_smoking-1026559_1920_scl-900x600.jpg 900w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/RS39152_smoking-1026559_1920_scl-768x512.jpg 768w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/RS39152_smoking-1026559_1920_scl-753x502.jpg 753w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/RS39152_smoking-1026559_1920_scl-203x135.jpg 203w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/RS39152_smoking-1026559_1920_scl.jpg 1200w\" sizes=\"auto, (max-width: 400px) 100vw, 400px\" \/><\/a>A doh\u00e1nyz\u00e1s az egyik legjelent\u0151sebb megel\u0151zhet\u0151 eg\u00e9szs\u00e9gk\u00e1ros\u00edt\u00f3 magatart\u00e1sforma, k\u00fcl\u00f6n\u00f6sen a sz\u00edv- \u00e9s \u00e9rrendszeri betegs\u00e9gek kock\u00e1zat\u00e1nak n\u00f6veked\u00e9se szempontj\u00e1b\u00f3l. Az ut\u00f3bbi \u00e9vek kutat\u00e1sai igazolt\u00e1k, hogy a doh\u00e1nyz\u00e1si szok\u00e1sok kialakul\u00e1s\u00e1ban nemcsak k\u00f6rnyezeti, hanem \u00f6r\u00f6kletes t\u00e9nyez\u0151k is szerepet j\u00e1tszanak. Vizsg\u00e1latunkban azt elemezt\u00fck, hogy a doh\u00e1nyz\u00e1ssal \u00f6sszef\u00fcgg\u0151 genetikai vari\u00e1nsok (SNP-k) befoly\u00e1solj\u00e1k-e a sz\u00edvfrekvencia v\u00e1ltoz\u00e1s\u00e1t fizikai terhel\u00e9st k\u00f6vet\u0151en.<\/p>\n<p>A vizsg\u00e1latba 661 magyar feln\u0151ttet vontunk be, akik a h\u00e1romperces YMCA l\u00e9pcs\u0151tesztet v\u00e9gezt\u00e9k el. A pulzussz\u00e1mot nyugalomban, k\u00f6zvetlen\u00fcl a terhel\u00e9s ut\u00e1n, valamint \u00f6t \u00e9s t\u00edz perc eltelt\u00e9vel hat\u00e1roztuk meg. Ezekb\u0151l az adatokb\u00f3l kisz\u00e1m\u00edtottuk a pulzussz\u00e1m v\u00e1ltoz\u00e1st (\u0394HR), a maxim\u00e1lis pulzussz\u00e1m ar\u00e1ny\u00e1t (HRmax%) \u00e9s a pulzussz\u00e1m-vissza\u00e1ll\u00e1si egy\u00fctthat\u00f3t. Kilenc SNP-t vizsg\u00e1ltunk, amelyek k\u00f6z\u00fcl h\u00e1rom \u2013 rs2235186-G (ADRB1), rs4142041-A (CTNNA3) \u00e9s rs578776-G (CHRNA3) \u2013 szignifik\u00e1ns \u00f6sszef\u00fcgg\u00e9st mutatott a terhel\u00e9s ut\u00e1ni magasabb pulzussz\u00e1mmal, a nagyobb \u0394HR-rel, a magasabb HRmax% \u00e9rt\u00e9kkel \u00e9s a nyugalmi pulzussz\u00e1m lassabb helyre\u00e1ll\u00e1s\u00e1val. Az ezen SNP-vari\u00e1nsok alapj\u00e1n k\u00e9pzett genetikai kock\u00e1zati pontsz\u00e1m szint\u00e9n szignifik\u00e1ns kapcsolatot mutatott az edz\u00e9s ut\u00e1ni sz\u00edvfrekvencia-v\u00e1ltoz\u00e1ssal.<\/p>\n<p>Eredm\u00e9nyeink arra utalnak, hogy a doh\u00e1nyz\u00e1si hajlamot befoly\u00e1sol\u00f3 genetikai t\u00e9nyez\u0151k a sz\u00edv auton\u00f3m szab\u00e1lyoz\u00e1s\u00e1t is \u00e9rinthetik, ami \u00faj lehet\u0151s\u00e9geket nyithat a szem\u00e9lyre szabott kardiovaszkul\u00e1ris kock\u00e1zatbecsl\u00e9sben \u00e9s -kezel\u00e9sben, k\u00fcl\u00f6n\u00f6sen olyan egy\u00e9nek eset\u00e9ben, akik genetikailag hajlamosak a doh\u00e1nyz\u00e1sra &#8211; \u00edrta \u00f6sszefoglal\u00f3j\u00e1ban dr. Pik\u00f3 P\u00e9ter.<\/p>\n<div class=\"keretes w-100\">\n<p>The Impact of Smoking-Associated Genetic Variants on Post-Exercise Heart Rate<br \/>\nHabib Al Ashkar (Doctoral School of Health Sciences, University of Debrecen; HUN-REN-UD Public Health Research Group, Department of Public Health and Epidemiology, Faculty of Medicine, University of Debrecen), Nihad Kharrat Helu (Doctoral School of Health Sciences, University of Debrecen), Nora Kovacs (HUN-REN-UD Public Health Research Group, Department of Public Health and Epidemiology, Faculty of Medicine, University of Debrecen; Department of Public Health and Epidemiology, Faculty of Medicine, University of Debrecen), Szilvia Fiatal (Department of Public Health and Epidemiology, Faculty of Medicine, University of Debrecen), Roza Adany (HUN-REN-UD Public Health Research Group, Department of Public Health and Epidemiology, Faculty of Medicine, University of Debrecen; Department of Public Health and Epidemiology, Faculty of Medicine, University of Debrecen; National Laboratory for Health Security, Center for Epidemiology and Surveillance, Semmelweis University; Department of Preventive Medicine and Public Health, Semmelweis University), Peter Piko (Department of Public Health and Epidemiology, Faculty of Medicine, University of Debrecen; <br \/>\nNational Laboratory for Health Security, Center for Epidemiology and Surveillance, Semmelweis University)<br \/>\nnt. J. Mol. Sci. 2025, 26(18), 8787; <br \/>\n<a href=\"https:\/\/doi.org\/10.3390\/ijms26188787\" target=\"_blank\" rel=\"noopener\">https:\/\/doi.org\/10.3390\/ijms26188787<\/a><\/p>\n<\/div>\n<h3><a id=\"intraoralis\"><\/a>Az intraor\u00e1lis szkennel\u00e9s, a sz\u00e1m\u00edt\u00f3g\u00e9p vez\u00e9relt gy\u00e1rt\u00e1s \u00e9s a teljes munkafolyamat pontoss\u00e1g m\u00e9r\u00e9s\u00e9nek egys\u00e9ges\u00edt\u00e9se virtu\u00e1lis illeszt\u00e9s m\u00f3dszer\u00e9vel sz\u00f3l\u00f3 korona eset\u00e9n<\/h3>\n<p><a href=\"https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/szken.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft size-medium wp-image-164154\" src=\"https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/szken-400x357.jpg\" alt=\"\" width=\"400\" height=\"357\" srcset=\"https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/szken-400x357.jpg 400w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/szken.jpg 676w\" sizes=\"auto, (max-width: 400px) 100vw, 400px\" \/><\/a>A digit\u00e1lis szkennel\u00e9s (IOS), tervez\u00e9s (CAD) \u00e9s gy\u00e1rt\u00e1s (CAM) gyorsabb\u00e1 tette a fogorvosi kezel\u00e9seket. Ugyanakkor ennek elterjed\u00e9s\u00e9t g\u00e1tolja, hogy az el\u00e9rhet\u0151 pontoss\u00e1gi adatok nem adnak ir\u00e1nymutat\u00e1st a klinikai sikeress\u00e9g szempontjaib\u00f3l. Kutat\u00e1sunk c\u00e9lja volt, hogy l\u00e9trehozzunk egy elj\u00e1r\u00e1st a munkafolyamat l\u00e9p\u00e9seinek pontoss\u00e1g\u00e1nak vizsg\u00e1lat\u00e1ra, amelyben a m\u00e9rt fizikai mennyis\u00e9g egys\u00e9ges \u00e9s a restaur\u00e1tum klinikai sikeress\u00e9g\u00e9vel \u00f6sszef\u00fcgg\u00e9sben van.<\/p>\n<p>Vizsg\u00e1latunkban egy koron\u00e1hoz el\u0151k\u00e9sz\u00edtett m\u0171fogat szkenneltunk be intraor\u00e1lis szkenner seg\u00edts\u00e9g\u00e9vel \u00e9s egy nagy pontoss\u00e1g\u00fa referencia szkennerrel, majd l\u00e9trehoztuk a CAD\/CAM koron\u00e1kat. Az \u00e1ltalunk kifejlesztett virtu\u00e1lis illeszt\u00e9s m\u00f3dszerrel meghat\u00e1roztuk a szkennel\u00e9s (1), a mar\u00e1s (2), \u00e9s a teljes munkafolyamat (3) eset\u00e9n a sz\u00e9li z\u00e1r\u00f3d\u00e1s pontoss\u00e1g\u00e1t, ami min\u00e9l kisebb, ann\u00e1l ink\u00e1bb jav\u00edtja a fogp\u00f3tl\u00e1s sikeress\u00e9g\u00e9t. Az intraor\u00e1lis szkennel\u00e9s (1) h\u00e1romszor pontosabb volt, mint a mar\u00e1si f\u00e1zis (2). A teljes munkafolyamatn\u00e1l (3) az \u00e1tlagos sz\u00e9lz\u00e1r\u00f3d\u00e1s 52 \u00b5m volt, ami b\u0151ven a klinikailag elfogadhat\u00f3 szint (120 \u00b5m) alatt volt. Az \u00faj elj\u00e1r\u00e1ssal siker\u00fclt bizony\u00edtani, hogy a CAD\/CAM technol\u00f3gi\u00e1val gy\u00e1rtott restaur\u00e1tumok alkalmasak klinikai felhaszn\u00e1l\u00e1sra &#8211; \u00edrta \u00f6sszefoglal\u00f3j\u00e1ban dr. V\u00e1g J\u00e1nos \u00e9s dr. Borbola D\u00e1niel.<\/p>\n<div class=\"keretes w-100\">\n<p>Unifying intraoral scanner, computer-aided manufacturing, and final crown accuracy: A virtual-fit method for marginal gap evaluation<br \/>\nDaniel Borbola (Department of Restorative Dentistry and Endodontics, Faculty of Dentistry, Semmelweis University), Janos Vag (Department of Restorative Dentistry and Endodontics, Faculty of Dentistry, Semmelweis University)<br \/>\nJournal of Dentistry, Volume 163, December 2025, 106113<br \/>\n<a href=\"https:\/\/doi.org\/10.1016\/j.jdent.2025.106113\" target=\"_blank\" rel=\"noopener\">https:\/\/doi.org\/10.1016\/j.jdent.2025.106113<\/a><\/p>\n<\/div>\n<h3><a id=\"prope\"><\/a>A proPE rendszerrel m\u00e9g pontosabb\u00e1 \u00e9s biztons\u00e1gosabb\u00e1 v\u00e1lhat a g\u00e9nszerkeszt\u00e9s<\/h3>\n<p><a href=\"https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/proPE-graphical-abstract.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft size-medium wp-image-164159\" src=\"https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/proPE-graphical-abstract-400x222.jpg\" alt=\"\" width=\"400\" height=\"222\" srcset=\"https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/proPE-graphical-abstract-400x222.jpg 400w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/proPE-graphical-abstract-900x500.jpg 900w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/proPE-graphical-abstract-768x427.jpg 768w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/proPE-graphical-abstract-753x419.jpg 753w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/proPE-graphical-abstract.jpg 1063w\" sizes=\"auto, (max-width: 400px) 100vw, 400px\" \/><\/a>A CRISPR\/Cas rendszer forradalmas\u00edtotta a g\u00e9nszerkeszt\u00e9st, a prime editing pedig ennek egy olyan \u00faj gener\u00e1ci\u00f3s v\u00e1ltozata, mellyel a DNS-szekvencia inform\u00e1ci\u00f3tartalma nagyobb DNS-t\u00f6r\u00e9s l\u00e9trehoz\u00e1sa n\u00e9lk\u00fcl, tetsz\u00e9s szerint m\u00f3dos\u00edthat\u00f3, az \u00e1ltalunk meghat\u00e1rozott helyen. A m\u00f3dszer ugyanakkor sok esetben m\u00e9g gyenge hat\u00e1sfok\u00fa, \u00e9s a komponensek kiterjedt finomhangol\u00e1s\u00e1t ig\u00e9nyli.<\/p>\n<p>Az \u00e1ltalunk kifejlesztett proPE rendszer er\u0151ss\u00e9ge, hogy \u00e9ppen azokban az esetekben hoz jelent\u0151s hat\u00e9konys\u00e1gjavul\u00e1st, ahol a klasszikus prime editing csak nagyon kis sz\u00e1zal\u00e9kban tudja l\u00e9trehozni a k\u00edv\u00e1nt m\u00f3dos\u00edt\u00e1st. Tov\u00e1bb\u00e1 cs\u00f6kkenti a komponensek optimaliz\u00e1l\u00e1si ig\u00e9ny\u00e9t is. A m\u00f3dszer a g\u00e9nszerkeszt\u00e9s biztons\u00e1goss\u00e1g\u00e1t is n\u00f6veli, mivel olyan esetekben is k\u00e9pes csak a tervezett helyen v\u00e9grehajtani a m\u00f3dos\u00edt\u00e1st, amikor a klasszikus prime editing alkalmaz\u00e1sa nem k\u00edv\u00e1nt m\u00f3dos\u00edt\u00e1sokat eredm\u00e9nyezne. A proPE tov\u00e1bbi fontos el\u0151nye, hogy megn\u00f6veli a hat\u00f3t\u00e1vols\u00e1got. Ez k\u00fcl\u00f6n\u00f6sen \u00edg\u00e9retes a j\u00f6v\u0151beli ter\u00e1pi\u00e1s alkalmaz\u00e1sok szempontj\u00e1b\u00f3l, mivel \u00edgy potenci\u00e1lisan korrig\u00e1lhat\u00f3v\u00e1 v\u00e1lhatnak az eddig prime editinggel nehezen el\u00e9rhet\u0151 patog\u00e9n pontmut\u00e1ci\u00f3k is &#8211; fogalmazott Simon Dorottya Anna.<\/p>\n<div class=\"keretes w-100\">\n<p>ProPE expands the prime editing window and enhances gene editing efficiency where prime editing is inefficient<br \/>\nSarah Laura Krausz (Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences; School of PhD Studies, Semmelweis University; Pannon Plazmid), Dorottya Anna Simon (Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences; School of PhD Studies, Semmelweis University), Zsuzsa Bartos (Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences), Zsuzsanna Bicz\u00f3k (Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences; School of PhD Studies, Semmelweis University; Biospir\u00e1l-2006), \u00c9va Varga (Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences; Biospir\u00e1l-2006; Institute of Biochemistry, HUN-REN Biological Research Centre; School of PhD Studies, University of Szeged), Krisztina Husz\u00e1r (Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences; School of PhD Studies, E\u00f6tv\u00f6s Lor\u00e1nd University), P\u00e9ter Istv\u00e1n Kulcs\u00e1r (Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences; Biospir\u00e1l-2006), Andr\u00e1s T\u00e1las (Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences), Zolt\u00e1n Ligeti (Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences; Institute of Biochemistry, HUN-REN Biological Research Centre; School of PhD Studies, University of Szeged), Ervin Welker (Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences; Institute of Biochemistry, HUN-REN Biological Research Centre)<br \/>\nNature Catalysis volume 8, pages 1100\u20131116 (2025).<br \/>\n<a href=\"https:\/\/doi.org\/10.1038\/s41929-025-01406-6\" target=\"_blank\" rel=\"noopener\">https:\/\/doi.org\/10.1038\/s41929-025-01406-6<\/a><\/p>\n<\/div>\n<h3><a id=\"hasnyalmirigy\"><\/a>A cholecystectomia \u00e9s az endoszk\u00f3pos retrogr\u00e1d cholangiopancreatographia (ERCP) biztons\u00e1g\u00e1nak \u00e9s hat\u00e9konys\u00e1g\u00e1nak vizsg\u00e1lata epek\u00f6vess\u00e9g okozta hasny\u00e1lmirigy-gyullad\u00e1sban a terhess\u00e9g sor\u00e1n: BORN vizsg\u00e1lat<\/h3>\n<p>Az akut hasny\u00e1lmirigy-gyullad\u00e1s a leggyakoribb k\u00f3rh\u00e1zi felv\u00e9telt ig\u00e9nyl\u0151 gasztroenterol\u00f3giai k\u00f3rk\u00e9p, \u00e9s b\u00e1r a terhess\u00e9g sor\u00e1n el\u0151fordul\u00f3 epek\u00f6vess\u00e9g okozta hasny\u00e1lmirigy-gyullad\u00e1s ritka, ugyanakkor kih\u00edv\u00e1st \u00e1ll\u00edt az orvosok el\u00e9. A terhess\u00e9g \u00f6nmag\u00e1ban rizik\u00f3faktort jelent az epek\u00f6vek kialakul\u00e1s\u00e1ra. Az \u00e1tlag n\u00e9pess\u00e9gben a nemzetk\u00f6zi ir\u00e1nyelvek az enyhe lefoly\u00e1s\u00fa epek\u00f6vess\u00e9g okozta, bili\u00e1ris hasny\u00e1lmirigy-gyullad\u00e1s ut\u00e1n korai cholecystectomi\u00e1t, epeh\u00f3lyag-elt\u00e1vol\u00edt\u00e1st javasolnak, az ism\u00e9telt hasny\u00e1lmirigy-gyullad\u00e1s, epeh\u00f3lyaggyullad\u00e1s vagy epe\u00fatgyullad\u00e1st megel\u0151z\u00e9s\u00e9re. Kutat\u00e1sunk sor\u00e1n a terhess\u00e9g sor\u00e1n kialakul\u00f3 bili\u00e1ris hasny\u00e1lmirigy-gyullad\u00e1s sor\u00e1n v\u00e9gzett endoszk\u00f3pos retrogr\u00e1d cholangiopancreatographia (ERCP), az epeutak vizsg\u00e1lat\u00e1ra alkalmas endoszk\u00f3pos beavatkoz\u00e1s, illetve a hasny\u00e1lmirigy-gyullad\u00e1st k\u00f6vet\u0151en lezajlott m\u0171t\u00e9t magzati \u00e9s anyai biztons\u00e1g\u00e1t \u00e9s hat\u00e9konys\u00e1g\u00e1t vizsg\u00e1ltuk.<\/p>\n<p>Nemzetk\u00f6zi, 19 centrum bevon\u00e1s\u00e1val v\u00e9gzett retrospekt\u00edv vizsg\u00e1latunk sor\u00e1n 14 orsz\u00e1g\u00f3l \u00f6sszesen 101 esetet analiz\u00e1ltunk. Az enyhe lefoly\u00e1s\u00fa bili\u00e1ris akut hasny\u00e1lmirigy-gyullad\u00e1st k\u00f6vet\u0151en m\u00e9g a terhess\u00e9g sor\u00e1n cholecystectomi\u00e1n \u00e1tes\u0151 p\u00e1ciensekn\u00e9l az ism\u00e9telt k\u00f3rh\u00e1zi felv\u00e9telt ig\u00e9nyl\u0151 rekurrens hasny\u00e1lmirigy-gyullad\u00e1s vagy epek\u00f6vess\u00e9g okozta komplik\u00e1ci\u00f3 kisebb ar\u00e1nyban fordult el\u0151 (0% vs. 24%; n = 0\/17 vs. n = 12\/49, p = 0.027). A seb\u00e9szeti sz\u00f6v\u0151dm\u00e9nyek nem k\u00fcl\u00f6nb\u00f6ztek a terhess\u00e9g alatt vagy ut\u00e1n v\u00e9gzett beavatkoz\u00e1sok k\u00f6z\u00f6tt (12% vs. 10%; n = 2\/17 vs. n = 3\/30; p &gt; 0.999). A terhess\u00e9g sor\u00e1n elv\u00e9gzett m\u0171t\u00e9tet k\u00f6vet\u0151en a p\u00e1ciensek 7.1%-ban (n = 1\/14) fordult el\u0151 korasz\u00fcl\u00e9s, m\u00edg a m\u00e1sik csoportban ez az ar\u00e1ny 11% (n = 5\/45) volt. Magzati vesztes\u00e9g csak az els\u0151 trimeszterben v\u00e9gzett m\u0171t\u00e9ti beavatkoz\u00e1st k\u00f6vet\u0151en fordult el\u0151 (n = 3\/17 vs. n = 1\/49). A magzati vesztes\u00e9g (9.1%, n = 2\/22 vs. 5.4%, n = 4\/74; p = 0.618) \u00e9s a korasz\u00fcl\u00e9s ar\u00e1nya (5.9%, n = 1\/17 vs. 12%, n = 8\/65; p = 0.677) nem mutatott szignifik\u00e1ns k\u00fcl\u00f6nbs\u00e9get a terhess\u00e9g alatt ERCP vizsg\u00e1laton \u00e1tesett p\u00e1ciensek \u00e9s azon p\u00e1ciensek k\u00f6z\u00f6tt, akik ezen a beavatkoz\u00e1son nem estek \u00e1t. Eredm\u00e9nyeink alapj\u00e1n a terhess\u00e9g sor\u00e1n el\u0151fordul\u00f3 enyhe lefoly\u00e1s\u00fa bili\u00e1ris akut hasny\u00e1lmirigy-gyullad\u00e1st k\u00f6vet\u0151en a cholecystectomia biztons\u00e1gosan elv\u00e9gezhet\u0151 a terhess\u00e9g m\u00e1sodik \u00e9s harmadik trimeszter\u00e9ben, m\u00edg az ERCP biztons\u00e1gosnak bizonyult a terhess\u00e9g b\u00e1rmely szakasz\u00e1ban &#8211; \u00edrta \u00f6sszefoglal\u00f3j\u00e1ban dr. Tarj\u00e1n Dorottya.<\/p>\n<div class=\"keretes w-100\">\n<p>Safety and Effectiveness of Cholecystectomy and Endoscopic Retrograde Cholangiopancreatography in Biliary Pancreatitis During Pregnancy: BORN Study<br \/>\nDorottya Tarj\u00e1n (Centre for Translational Medicine, Semmelweis University; Institute of Pancreatic Diseases, Semmelweis University; Institute for Translational Medicine, Medical School, University of P\u00e9cs), Eszter \u00c1gnes Szalai (Centre for Translational Medicine, Semmelweis University; Department of Restorative Dentistry and Endodontics, Semmelweis University), B\u00e1lint Er\u0151ss (Centre for Translational Medicine, Semmelweis University; Institute of Pancreatic Diseases, Semmelweis University; Institute for Translational Medicine, Medical School, University of P\u00e9cs), P\u00e9ter Jen\u0151 Hegyi (Centre for Translational Medicine, Semmelweis University; Institute of Pancreatic Diseases, Semmelweis University), Vasile Liviu Drug (Centre for Translational Medicine, Semmelweis University; Grigore T. Popa University of Medicine and Pharmacy), Serge Chooklin (Lviv Regional Clinical Hospital), Michael Hirth (Department of Medicine II, Medical Faculty Mannheim, University of Heidelberg), Gabriel Sandblom (Department of Clinical Science and Education S\u00f6dersjukhuset, Karolinska Institutet; Department of Surgery, S\u00f6dersjukhuset), Vanessa Sandblom (Karolinska Institutet), \u00c5sa Edergren (Department of Clinical Science and Education S\u00f6dersjukhuset, Karolinska Institutet; Department of Surgery, S\u00f6dersjukhuset), Ahmed Tlili (Department of General Surgery, University Hospital of Gabes, Faculty of Medicine of Sfax), Sami Fendri (Department of General Surgery, Habib Bourguiba Hospital, Faculty of Medicine of Sfax), Simon Sirtl (Department of Medicine II, LMU University Hospital Munich), Daniel de la Iglesia Grac\u00eda (Gastroenterology Department, University Hospital of Santiago de Compostela), Floreta Kurti (Department of Gastroenterology and Hepatology, University Hospital Center &#8222;Mother Theresa&#8221;; University of Medicine, Tirana), Dong Wu (Department of Gastroenterology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College), Adriana Gherbon (Department VII Internal Medicine &#8211; Diabetes, Nutrition, Metabolic Diseases, and Systemic Rheumatology, &#8222;Victor Babes&#8221; University of Medicine and Pharmacy; Centre of Molecular Research in Nephrology and Vascular Disease, &#8222;Victor Babes&#8221; University of Medicine and Pharmacy; Diabetes, Nutrition, and Metabolic Diseases, &#8222;Pius Brinzeu&#8221; Emergency Hospital), \u0141ukasz Nawacki (Collegium Medicum, The Jan Kochanowski University), Alexandru Constantinescu (Gastroenterology Department, Carol Davila University of Medicine and Pharmacy, The University Emergency Hospital of Bucharest), Natalia V Shirinskaya (Omsk Medical and Diagnostic Center \u00abDoverie\u00bb, Omsk State Medical University), Alexander N Zolotov (Central Research Laboratory, Department of Pathophysiology, Omsk State Medical University), Sanjay Pandanaboyana (HPB Transplant Unit, Freeman Hospital), Tsukasa Ikeura (Division of Gastroenterology and Hepatology, Kansai Medical University Hospital), Tiago C\u00fardia Gon\u00e7alves (Gastroenterology Department, Unidade Local de Sa\u00fade do Alto Ave; Life and Health Sciences Research Institute &lt;ICVS&gt;, School of Medicine, University of Minho; ICVS\/3B&#8217;s, PT Government Associate Laboratory), Louise Rasmussen (Department of Surgical Gastroenterology, University Hospital of Hvidovre), Bodil Andersson (Department of Surgery, Sk\u00e5ne University Hospital; Institution for Clinical Sciences Lund, Surgery, Lund University), Ahmed Bouzid (University Tunis El Manar; Department of General Surgery, Mahmoud Matri Hospital), Ahmed Saidani (Department of General Surgery, Mahmoud Matri Hospital), N\u00e1ndor \u00c1cs (Department of Obstetrics and Gynaecology, Semmelweis University), Zolt\u00e1n Sipos (Institute for Translational Medicine, Medical School, University of P\u00e9cs), Nelli Farkas (Institute for Translational Medicine, Medical School, University of P\u00e9cs), Bal\u00e1zs Tihanyi (Department for Surgery, Hungarian Defence Forces &#8211; Medical Centre), Brigitta Teutsch (Centre for Translational Medicine, Semmelweis University; Institute for Translational Medicine, Medical School, University of P\u00e9cs; Department of Radiology, Medical Imaging Centre, Semmelweis University), Johan Nilsson (Department of Translational Medicine, Lund University and Skane University Hospital), Alexandra Mik\u00f3 (Centre for Translational Medicine, Semmelweis University; Institute for Translational Medicine, Medical School, University of P\u00e9cs; Translational Pancreatology Research Group, Interdisciplinary Centre of Excellence for Research Development and Innovation, University of Szeged; Department of Medical Genetics, Medical School, University of P\u00e9cs), P\u00e9ter Hegyi (Centre for Translational Medicine, Semmelweis University; Institute of Pancreatic Diseases, Semmelweis University;Institute for Translational Medicine, Medical School, University of P\u00e9cs; Translational Pancreatology Research Group, Interdisciplinary Centre of Excellence for Research Development and Innovation, University of Szeged)<br \/>\nUnited European Gastroenterol J. 2025 Nov;13(9):1803-1811. doi: 10.1002\/ueg2.70121. Epub 2025 Oct 4.<br \/>\n<span class=\"id-label\" style=\"font-size: 1rem\">DOI: <\/span><a class=\"id-link\" href=\"https:\/\/doi.org\/10.1002\/ueg2.70121\" target=\"_blank\" rel=\"noopener\">10.1002\/ueg2.70121<\/a><\/p>\n<\/div>\n<h3><a id=\"markerpredict\"><\/a>\u00daj megk\u00f6zel\u00edt\u00e9s daganatter\u00e1pi\u00e1k hat\u00e9konys\u00e1g\u00e1nak el\u0151rejelz\u00e9s\u00e9re biomarkerek rendszerszint\u0171 azonos\u00edt\u00e1s\u00e1val<\/h3>\n<figure id=\"attachment_164162\" aria-describedby=\"caption-attachment-164162\" style=\"width: 360px\" class=\"wp-caption alignleft\"><a href=\"https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/schulc.png\"><img loading=\"lazy\" decoding=\"async\" class=\"size-medium wp-image-164162\" src=\"https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/schulc-360x400.png\" alt=\"\" width=\"360\" height=\"400\" srcset=\"https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/schulc-360x400.png 360w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/schulc-719x800.png 719w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/schulc-768x854.png 768w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/schulc-1381x1536.png 1381w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/schulc-1842x2048.png 1842w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/schulc-753x837.png 753w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/schulc.png 2000w\" sizes=\"auto, (max-width: 360px) 100vw, 360px\" \/><\/a><figcaption id=\"caption-attachment-164162\" class=\"wp-caption-text\">A step-by-step approach to the network-topology-based identification of predictive oncotherapeutical biomarkers.<\/figcaption><\/figure>\n<p>A tanulm\u00e1ny a MarkerPredict nev\u0171 \u00faj biomarker-val\u00f3sz\u00edn\u0171s\u00edt\u0151 m\u00f3dszert mutatja be, amely az\u00e9rt k\u00e9sz\u00fclt, hogy seg\u00edtse az onkol\u00f3gusokat el\u0151re jelezni, hogy kin\u00e9l lehet hat\u00e9kony egy c\u00e9lzott daganatellenes ter\u00e1pia. A m\u00f3dszer a sejtekben m\u0171k\u00f6d\u0151 jel\u00e1tviteli h\u00e1l\u00f3zatok, azaz a feh\u00e9rj\u00e9k k\u00f6zti szab\u00e1lyoz\u00f3 kapcsolatok elemz\u00e9s\u00e9t (h\u00e1l\u00f3zat topol\u00f3gia), \u00e9s a feh\u00e9rj\u00e9k szerkezeti rendezetlens\u00e9gi adatait kombin\u00e1lja g\u00e9pi tanul\u00e1ssal. A modell 880 ismert gy\u00f3gyszerc\u00e9lpont\u2013feh\u00e9rje-p\u00e1roson tanult, \u00e9s az algoritmus 70\u201396 sz\u00e1zal\u00e9k k\u00f6z\u00f6tti pontoss\u00e1ggal tudta megk\u00fcl\u00f6nb\u00f6ztetni a val\u00f3s biomarkereket a nem-biomarkerekt\u0151l. A m\u00f3dszer pontoss\u00e1g\u00e1t tov\u00e1bb fokozand\u00f3, a szerz\u0151k 32 modell kombin\u00e1l\u00e1s\u00e1val kialak\u00edtott\u00e1k a Biomarker El\u0151rejelz\u0151 Pontsz\u00e1mot a leg\u00edg\u00e9retesebb jel\u00f6ltek megtal\u00e1l\u00e1s\u00e1ra. Ezut\u00e1n 3670 p\u00e1ron alkalmazva a m\u00f3dszert, a MarkerPredict t\u00f6bb mint 2084 potenci\u00e1lis \u00faj gy\u00f3gyszerhat\u00e1st el\u0151rejelz\u0151 biomarkert azonos\u00edtott. Ezek k\u00f6z\u00fcl 426 olyan volt, amit az \u00f6sszes modell konzisztensen j\u00f3nak jel\u00f6lt. K\u00f6z\u00fcl\u00fck az egyik leg\u00edg\u00e9retesebb, r\u00e9szletesen bemutatott jel\u00f6lt az ERK1 nev\u0171 feh\u00e9rje, amelyet a modell az BCL2\u2013g\u00e1tl\u00f3 ter\u00e1pi\u00e1k biomarker\u00e9nek javasol magas pontsz\u00e1mmal.<\/p>\n<p>A MarkerPredict m\u00f3dszerrel el\u00e9rt eredm\u00e9nyek alapj\u00e1n, h\u00e1l\u00f3zatos \u00e9s feh\u00e9rjeszerkezeti jellemz\u0151k kombin\u00e1l\u00e1sa r\u00e9v\u00e9n \u00faj, kor\u00e1bban fel nem ismert biomarkerek azonos\u00edt\u00e1sa t\u00f6rt\u00e9nhet meg, melyek tov\u00e1bbi, k\u00eds\u00e9rletekkel \u00e9s betegmint\u00e1kkal val\u00f3 igazol\u00e1sra alkalmasak. Az igazolt biomarkerek pedig hossz\u00fa t\u00e1von seg\u00edthetik azt, hogy a betegek sz\u00e1m\u00e1ra a megfelel\u0151 gy\u00f3gyszeres kezel\u00e9s ker\u00fclj\u00f6n kiv\u00e1laszt\u00e1sra &#8211; fogalmazott dr. Schulc Kl\u00e1ra, dr. Veres D\u00e1niel \u00e9s dr. Csermely P\u00e9ter.<\/p>\n<div class=\"keretes w-100\">\n<p>MarkerPredict: predicting clinically relevant predictive biomarkers with machine learning<br \/>\nDaniel V. Veres (Department of Molecular Biology, Semmelweis University; Turbine Ltd), Peter Csermely (Department of Molecular Biology, Semmelweis University), Kl\u00e1ra Schulc (Department of Molecular Biology, Semmelweis University; Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University)<br \/>\nnpj Systems Biology and Applications volume 11, Article number: 132 (2025).<br \/>\n<a href=\"https:\/\/doi.org\/10.1038\/s41540-025-00603-0\" target=\"_blank\" rel=\"noopener\">https:\/\/doi.org\/10.1038\/s41540-025-00603-0<\/a><\/p>\n<\/div>\n<h3><a id=\"toll\"><\/a>A Toll-like receptorok, antimikrobi\u00e1lis feh\u00e9rj\u00e9k \u00e9s b\u00e9lny\u00e1lkah\u00e1rty\u00e1t bor\u00edt\u00f3 bakteri\u00e1lis biofilm v\u00e1ltoz\u00e1sainak vizsg\u00e1lata a nem-szteroid gyullad\u00e1scs\u00f6kkent\u0151k \u00e1ltal okozott b\u00e9lk\u00e1rosod\u00e1s \u00e1llatk\u00eds\u00e9rletes modellj\u00e9ben<\/h3>\n<p><a href=\"https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/zadori-scaled.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft size-medium wp-image-164168\" src=\"https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/zadori-400x299.jpg\" alt=\"\" width=\"400\" height=\"299\" srcset=\"https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/zadori-400x299.jpg 400w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/zadori-900x674.jpg 900w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/zadori-768x575.jpg 768w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/zadori-1536x1150.jpg 1536w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/zadori-2048x1533.jpg 2048w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/zadori-753x564.jpg 753w\" sizes=\"auto, (max-width: 400px) 100vw, 400px\" \/><\/a>A nem-szteroid gyullad\u00e1scs\u00f6kkent\u0151k (NSAID-ok) kr\u00f3nikus haszn\u00e1lata k\u00e1ros\u00edthatja a v\u00e9konyb\u00e9l ny\u00e1lkah\u00e1rty\u00e1j\u00e1t, \u00e9s v\u00e1ltoz\u00e1sokat eredm\u00e9nyezhet a b\u00e9l mikrobi\u00f3ta \u00f6sszet\u00e9tel\u00e9ben (diszbi\u00f3zis). B\u00e1r az NSAID-ok \u00e1ltal kiv\u00e1ltott diszbi\u00f3zis r\u00e9g\u00f3ta ismert \u00e9s bizony\u00edtottan hozz\u00e1j\u00e1rul a b\u00e9lk\u00e1rosod\u00e1s (enterop\u00e1tia) kialakul\u00e1s\u00e1hoz, a gazdaszervezet \u00e9s a v\u00e9konyb\u00e9l-bakt\u00e9riumok k\u00f6z\u00f6tti k\u00f6lcs\u00f6nhat\u00e1sok v\u00e1ltoz\u00e1sai enterop\u00e1ti\u00e1ban jelenleg nagyr\u00e9szt felt\u00e1ratlanok. Publik\u00e1ci\u00f3nkban indomethacinnal (IND) kiv\u00e1ltott enterop\u00e1ti\u00e1ban vizsg\u00e1ltuk hat Toll-like receptor (TLR) \u00e9s h\u00e1rom antimikrobi\u00e1lis peptid (AMP) expresszi\u00f3j\u00e1nak kapcsolat\u00e1t a gyullad\u00e1ssal \u00e9s a diszbi\u00f3zissal, valamint a v\u00e9konyb\u00e9l ny\u00e1lkah\u00e1rty\u00e1j\u00e1n tal\u00e1lhat\u00f3 bakteri\u00e1lis biofilm szerkezeti v\u00e1ltoz\u00e1saival patk\u00e1nyokban.<\/p>\n<p>Igazoltuk, hogy az IND-enterop\u00e1tia hat\u00e1ssal van a b\u00e9lben tal\u00e1lhat\u00f3 TLR-ek \u00e9s AMP-k t\u00f6bbs\u00e9g\u00e9nek expresszi\u00f3s mint\u00e1zat\u00e1ra: a TLR1, TLR2 \u00e9s a cathelicidin (CAMP) expresszi\u00f3ja a kezel\u00e9s hat\u00e1s\u00e1ra fokoz\u00f3dott, a TLR5 expresszi\u00f3ja cs\u00f6kkent, m\u00edg a TLR4 szintje csup\u00e1n kis m\u00e9rt\u00e9kben v\u00e1ltozott. Meg\u00e1llap\u00edtottuk tov\u00e1bb\u00e1, hogy a betegs\u00e9g korai szakasz\u00e1ban a TLR1, TLR2, TLR5 \u00e9s a CAMP v\u00e1ltoz\u00e1sai els\u0151sorban a gyullad\u00e1ssal, m\u00edg a TLR4 \u00e9s a defenzinek (Defa5, Defb2) m\u00f3dosul\u00e1sai ink\u00e1bb a diszbi\u00f3zissal hozhat\u00f3k \u00f6sszef\u00fcgg\u00e9sbe. Emellett els\u0151k\u00e9nt igazoltuk, hogy enterop\u00e1tia sor\u00e1n a ny\u00e1lkah\u00e1rty\u00e1n tal\u00e1lhat\u00f3 bakteri\u00e1lis biofilm is k\u00e1rosodik. Eredm\u00e9nyeink hozz\u00e1j\u00e1rulhatnak az NSAID-enterop\u00e1tia sor\u00e1n lej\u00e1tsz\u00f3d\u00f3 folyamatok jobb meg\u00e9rt\u00e9s\u00e9hez, ez\u00e1ltal pedig \u00faj ter\u00e1pi\u00e1s c\u00e9lpontok azonos\u00edt\u00e1s\u00e1hoz &#8211; fogalmazott \u00f6sszefoglal\u00f3j\u00e1ban dr. Z\u00e1dori Zolt\u00e1n.<\/p>\n<div class=\"keretes w-100\">\n<p>Oral indomethacin modifies small intestine biofilms and host-microbe interaction mediators<br \/>\nArezoo Haghighi (Department of Pharmacology and Pharmacotherapy, Semmelweis University; Center for Pharmacology and Drug Research &amp; Development, Semmelweis University), Andr\u00e1s S. T\u00f3th (Department of Pharmacology and Pharmacotherapy, Semmelweis University; Center for Pharmacology and Drug Research &amp; Development, Semmelweis University), Zsuzsanna O. Demeter (Department of Pharmacology and Pharmacotherapy, Semmelweis University; Center for Pharmacology and Drug Research &amp; Development, Semmelweis University), Barbara Hutka (Department of Pharmacology and Pharmacotherapy, Semmelweis University; Pharmacological and Drug Safety Research, Gedeon Richter Plc), Anna Zsidai (Department of Pharmacology and Pharmacotherapy, Semmelweis University; Center for Pharmacology and Drug Research &amp; Development, Semmelweis University), Lili Lengyel (Department of Pharmacology and Pharmacotherapy, Semmelweis University; Center for Pharmacology and Drug Research &amp; Development, Semmelweis University), Samaneh Haghighi (Institute of Translational Medicine, Semmelweis University), Melissa Pannier (Toulouse University, IRSD, INSERM, INRAe, ENVT), Guillaume Le Cosquer (Toulouse University, IRSD, INSERM, INRAe, ENVT; Department of Gastroenterology and Pancreatology, Toulouse University Hospital &lt;CHU Toulouse&gt;), Elodie S. Meunier (Toulouse University, IRSD, INSERM, INRAe, ENVT), Bence \u00c1gg (Center for Pharmacology and Drug Research &amp; Development, Semmelweis University; Cardiometabolic and HUN-REN-SU System Pharmacology Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University; Pharmahungary Group), N\u00f3ra Makra (Institute of Medical Microbiology, Semmelweis University), Eszter Ostorh\u00e1zi (Institute of Medical Microbiology, Semmelweis University), Bal\u00e1zs Ligeti (Faculty of Information Technology and Bionics, P\u00e1zm\u00e1ny P\u00e9ter Catholic University), Kriszti\u00e1n Kov\u00e1cs (Department of Laboratory Medicine, Semmelweis University), \u00c1gnes Kelemen (Department of Histopathology, Central Hospital of Northern Pest &#8211; Military Hospital), Anna Jakab (Department of Pathology, Forensic and Insurance Medicine, Semmelweis University), Gerda Wachtl (Department of Pharmacology and Pharmacotherapy, Semmelweis University; Center for Pharmacology and Drug Research &amp; Development, Semmelweis University), G\u00e1bor K\u00f6k\u00e9ny (Institute of Translational Medicine, Semmelweis University; International Nephrology Research and Training Center, Semmelweis University), D\u00f3ra Szab\u00f3 (Institute of Medical Microbiology, Semmelweis University; HUN-REN Human Microbiota Study Group, Institute of Medical Microbiology, Semmelweis University), P\u00e9ter Ferdinandy (Center for Pharmacology and Drug Research &amp; Development, Semmelweis University; Cardiometabolic and HUN-REN-SU System Pharmacology Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University; Pharmahungary Group), Jean-Paul Motta (Toulouse University, IRSD, INSERM, INRAe, ENVT), Nathalie Vergnolle (Toulouse University, IRSD, INSERM, INRAe, ENVT), Kl\u00e1ra Gyires (Department of Pharmacology and Pharmacotherapy, Semmelweis University; Center for Pharmacology and Drug Research &amp; Development, Semmelweis University), Zolt\u00e1n S. Z\u00e1dori (Department of Pharmacology and Pharmacotherapy, Semmelweis University; Center for Pharmacology and Drug Research &amp; Development, Semmelweis University)<br \/>\nLife Sciences, Volume 384, 1 January 2026, 124114<br \/>\n<a href=\"https:\/\/doi.org\/10.1016\/j.lfs.2025.124114\" target=\"_blank\" rel=\"noopener\">https:\/\/doi.org\/10.1016\/j.lfs.2025.124114<\/a><\/p>\n<\/div>\n<h3><a id=\"pitvari\"><\/a>Az atorvasztatin hat\u00e1sa a bal pitvari funkci\u00f3ra antraciklin alap\u00fa kemoter\u00e1pi\u00e1ban<\/h3>\n<p><a href=\"https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/jvencel.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft size-medium wp-image-164169\" src=\"https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/jvencel-400x245.png\" alt=\"\" width=\"400\" height=\"245\" srcset=\"https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/jvencel-400x245.png 400w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/jvencel-900x551.png 900w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/jvencel-768x470.png 768w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/jvencel-753x461.png 753w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/jvencel-620x380.png 620w, https:\/\/semmelweis.hu\/hirek\/files\/2026\/01\/jvencel.png 1436w\" sizes=\"auto, (max-width: 400px) 100vw, 400px\" \/><\/a>A STOP-CA klinikai vizsg\u00e1lat azt vizsg\u00e1lta, hogy az atorvastatin nev\u0171 koleszterincs\u00f6kkent\u0151 gy\u00f3gyszer k\u00e9pes-e megv\u00e9deni a sz\u00edvet az antraciklin t\u00edpus\u00fa daganatellenes kezel\u00e9sek mell\u00e9khat\u00e1sait\u00f3l. Az antraciklinek hat\u00e9konyak egyes leuk\u00e9mi\u00e1k, limf\u00f3m\u00e1k \u00e9s eml\u0151daganatok kezel\u00e9s\u00e9ben, azonban k\u00e1ros\u00edthatj\u00e1k a sz\u00edvet.<\/p>\n<p>A kutat\u00e1sban r\u00e9sztvev\u0151 betegeket v\u00e9letlenszer\u0171en k\u00e9t egyenl\u0151 csoportra osztottak: az egyik atorvasztatint kapott, a m\u00e1sik placeb\u00f3t (hat\u00f3anyag n\u00e9lk\u00fcli tablett\u00e1t). A STOP-CA vizsg\u00e1lat els\u0151dleges eredm\u00e9nyei a sz\u00edv bal kamr\u00e1ja funkci\u00f3t v\u00e9d\u0151 hat\u00e1st igazoltak az atorvasztatint kap\u00f3 csoportn\u00e1l. A sz\u00edv bal pitvar\u00e1ra gyakorolt hat\u00e1sokat azonban eddig nem vizsg\u00e1lt\u00e1k. A kemoter\u00e1pia kezdete el\u0151tt \u00e9s 12 h\u00f3nap ut\u00e1n sz\u00edv m\u00e1gneses rezonanci\u00e1s (CMR) felv\u00e9teleket k\u00e9sz\u00fcltek, a bal pitvari funkci\u00f3, benne a longitudin\u00e1lis falfesz\u00fcl\u00e9s m\u00e9r\u00e9s\u00e9vel, meghat\u00e1roz\u00e1sa c\u00e9lj\u00e1b\u00f3l. Az eredm\u00e9nyek alapj\u00e1n az antraciklin-kezel\u00e9s ut\u00e1n mindk\u00e9t csoportban m\u00e9rs\u00e9kelten romlott a bal pitvar m\u0171k\u00f6d\u00e9se, de az atorvasztatin nem ny\u00fajtott v\u00e9delmet ez ellen. A bal pitvari funkci\u00f3 roml\u00e1sa az 50 \u00e9v feletti betegnekn\u00e9l kifejezettebb volt &#8211; \u00edrta \u00f6sszefoglal\u00f3j\u00e1ban dr. Juh\u00e1sz Vencel.<\/p>\n<div class=\"keretes w-100\">\n<p>Atorvastatin and left atrial function during anthracycline-based chemotherapy<br \/>\nVencel Juhasz (Cardiovascular Imaging Research Center, Division of Cardiology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School; Heart and Vascular Center, Semmelweis University), Zsofia D. Drobni (Heart and Vascular Center, Semmelweis University), Thiago Quinaglia (Cardiovascular Imaging Research Center, Division of Cardiology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School), Hannah K. Gilman (Cardiovascular Imaging Research Center, Division of Cardiology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School), Giselle Alexandra Suero-Abreu (Cardiovascular Imaging Research Center, Division of Cardiology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School), Azin Ghamari (Cardiovascular Imaging Research Center, Division of Cardiology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School), Julius C. Heemelaar (Cardiovascular Imaging Research Center, Division of Cardiology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School; Leiden University Medical Center, Cardiology Department), Donna S. Neuberg (Department of Data Science, Dana-Farber Cancer Institute), Yuchi Han (Division of Cardiology, Hospital of the University of Pennsylvania), Bonnie Ky (Division of Cardiology, Hospital of the University of Pennsylvania), Raymond Y. Kwong (Cardiology Division, Brigham and Women\u2019s Hospital), James L. Januzzi (Division of Cardiology, Massachusetts General Hospital, Harvard Medical School; Baim Institute for Clinical Research), Aarti Asnani (Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School), Negareh Mousavi (Division of Cardiology, McGill University Hospital), Robert A. Redd (Leiden University Medical Center, Cardiology Department), Michael Jerosch-Herold (Department of Radiology, Brigham and Women\u2019s Hospital), Marielle Scherrer-Crosbie (Division of Cardiology, Hospital of the University of Pennsylvania), Tomas G. Neilan (Cardiovascular Imaging Research Center, Division of Cardiology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School; Cardiology Division, Brigham and Women\u2019s Hospital)<br \/>\nJournal of Cardiovascular Magnetic Resonance Volume 27, Issue 2, Winter 2025, 101946.<br \/>\n<a href=\"https:\/\/doi.org\/10.1016\/j.jocmr.2025.101946\" target=\"_blank\" rel=\"noopener\">https:\/\/doi.org\/10.1016\/j.jocmr.2025.101946<\/a><\/p>\n<\/div>\n<p>A r\u00f6vid \u00f6sszefoglal\u00f3kat a tudom\u00e1nyos publik\u00e1ci\u00f3k szerz\u0151i k\u00e9sz\u00edtett\u00e9k.<br \/>\nSzerkesztette: Szab\u00f3 \u00c1d\u00e1m<br \/>\nFot\u00f3: a publik\u00e1ci\u00f3kb\u00f3l sz\u00e1rmaz\u00f3 k\u00e9pek; illusztr\u00e1ci\u00f3 (Semmelweis Egyetem)<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cikksorozatunkban az egyetemhez k\u00f6thet\u0151 D1 min\u0151s\u00edt\u00e9s\u0171 tudom\u00e1nyos k\u00f6zlem\u00e9nyekr\u0151l olvashat\u00f3 r\u00f6vid \u00f6sszefoglal\u00f3.<\/p>\n","protected":false},"author":101751,"featured_media":102156,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[161,168],"tags":[4179,2408,4276],"class_list":["post-164138","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-tudomany","category-kiemelt","tag-alhonlapokra","tag-mki-alairas","tag-tudomanyos-hirado"],"acf":[],"_links":{"self":[{"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/posts\/164138","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/users\/101751"}],"replies":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/comments?post=164138"}],"version-history":[{"count":7,"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/posts\/164138\/revisions"}],"predecessor-version":[{"id":164315,"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/posts\/164138\/revisions\/164315"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/media\/102156"}],"wp:attachment":[{"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/media?parent=164138"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/categories?post=164138"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/tags?post=164138"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}